(1) Tolosa E, Wenning G, Poewe W. The diagnosis

(1) Tolosa E, Wenning G, Poewe W. The diagnosis

2014
Bibliografía
(1) Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease.
2006;5:75-86.
(2) Garcia-Ramos R, Lopez Valdes E, Ballesteros L, Jesus S, Mir P. The social
impact of Parkinson's disease in Spain: Report by the Spanish Foundation for
the Brain. Neurologia 2013 Jun 28.
(3) Olanow C.
The pathogenesis of cell death in Parkinson’s disease 22Suppl17:S335-42.
Mov Disord 2007(22 Suppl):S335-342.
(4) Hornykiewicz O. The tropical localization and content of noradrenalin and
dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and
patients with Parkinson’s disease. Wien Klin Wochenschr 1963;75:309-12.
(5) Javoy-Agid, F. Ruberg, M. Taquet, H. Studler, JM. Garbarg, M. Llorens, C.
et al. Biochemical neuroanatomy of the human substantia nigra (pars compacta) in normal and Parkinsonian subjects. Adv Neurol 1982;35:151-63.
(6) Guía oficial de práctica clínica en enfermedad de Parkinson 2009.
Barcelona: Sociedad Española de Neurología; Thomson Reuters; 2009.
(7) Snyder CH, Adler CH. The patient with Parkinson's disease: part I-treating
the motor symptoms; part II-treating the nommotor symptoms. J Am Acad
Nurse Pract 2007;19:179-197.
(8) Kulisevskya J, Luquin M, Arbeloc J, Burguerad J, Carrillo F. Enfermedad de
Parkinson Avanzada. Caracteristicas Clínicas y Tratamiento. Parte II.
Neurologia 2013;28(9)(558-583).
(9) Estudio Cepa. Informe de evaluación por Comité de Expertos. SEN 2014.
(10) Antonini A, Isaias IU, Canesi M, Zibetti M, Mancini F, Manfredi L, et al.
Duodenal levodopa infusion for advanced Parkinson's disease: 12-month
treatment outcome. Mov Disord 2007 Jun 15;22(8):1145-1149.
(11) Deuschl G, Paschen S, Witt K. Clinical outcome of deep brain stimulation
for Parkinson's disease. Handb Clin Neurol 2013;116:107-128.
(12) Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann
L, et al. Neurostimulation for Parkinson's disease with early motor
complications. N Engl J Med 2013 Feb 14;368(7):610-622.
(13) Takats A, Nagy H, Radics P, Toth A, Tamas G. Treatment possibilities in
advanced Parkinson's disease. Ideggyogy Sz 2013 Nov 30;66(11-12):365-371.
(14) Tamas G, Takats A, Radics P, Rozsa I, Csibri E, Rudas G, et al. Efficacy of
deep brain stimulation in our patients with Parkinson's disease. Ideggyogy Sz
2013 Mar 30;66(3-4):115-120.
(15) Zibetti M, Merola A, Ricchi V, Marchisio A, Artusi CA, Rizzi L, et al. Longterm duodenal levodopa infusion in Parkinson's disease: a 3-year motor and
cognitive follow-up study. J Neurol 2013 Jan;260(1):105-114.
(16) Amara AW, Standaert DG, Guthrie S, Cutter G, Watts RL, Walker HC.
Unilateral subthalamic nucleus deep brain stimulation improves sleep quality in
Parkinson's disease. Parkinsonism Relat Disord 2012 Jan;18(1):63-68.
(17) Fasano A, Ricciardi L, Lena F, Bentivoglio AR, Modugno N. Intrajejunal
levodopa infusion in advanced Parkinson's disease: long-term effects on motor
and non-motor symptoms and impact on patient's and caregiver's quality of life.
Eur Rev Med Pharmacol Sci 2012 Jan;16(1):79-89.
(18) Nyholm D. Duodopa(R) treatment for advanced Parkinson's disease: a
review of efficacy and safety. Parkinsonism Relat Disord 2012 Sep;18(8):916929.
(19) Palhagen SE, Dizdar N, Hauge T, Holmberg B, Jansson R, Linder J, et al.
Interim analysis of long-term intraduodenal levodopa infusion in advanced
Parkinson disease. Acta Neurol Scand 2012 Dec;126(6):e29-33.
(20) Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, et al.
Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor
and nonmotor effects. Clin Neuropharmacol 2012 Sep-Oct;35(5):205-207.
(21) Santos-Garcia D, Macias M, Llaneza M, Fuster-Sanjurjo L, Echarri-Piudo
A, Belmonte S, et al. Experience with continuous levodopa enteral infusion
(Duodopa((R))) in patients with advanced Parkinson's disease in a secondary
level hospital. Neurologia 2010 Nov-Dec;25(9):536-543.
(22) Nazzaro JM, Pahwa R, Lyons KE. The impact of bilateral subthalamic
stimulation on non-motor symptoms of Parkinson's disease. Parkinsonism Relat
Disord 2011 Sep;17(8):606-609.
(23) Ferrara J, Diamond A, Hunter C, Davidson A, Almaguer M, Jankovic J.
Impact of STN-DBS on life and health satisfaction in patients with Parkinson's
disease. J Neurol Neurosurg Psychiatry 2010 Mar;81(3):315-319.
(24) Puente V, De Fabregues O, Oliveras C, Ribera G, Pont-Sunyer C, Vivanco
R, et al. Eighteen month study of continuous intraduodenal levodopa infusion in
patients with advanced Parkinson's disease: impact on control of fluctuations
and quality of life. Parkinsonism Relat Disord 2010 Mar;16(3):218-221.
(25) Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, et al.
Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of
effects on nonmotor symptoms and quality of life. Mov Disord 2009 Jul
30;24(10):1468-1474.
(26) Nyholm D, Constantinescu R, Holmberg B, Dizdar N, Askmark H.
Comparison of apomorphine and levodopa infusions in four patients with
Parkinson's disease with symptom fluctuations. Acta Neurol Scand 2009
May;119(5):345-348.
(27) Antonini A, Mancini F, Canesi M, Zangaglia R, Isaias IU, Manfredi L, et al.
Duodenal levodopa infusion improves quality of life in advanced Parkinson's
disease. Neurodegener Dis 2008;5(3-4):244-246.
(28) Antonini A, Odin P, Opiano L, Tomantschger V, Pacchetti C, Pickut B, et al.
Effect and safety of duodenal levodopa infusion in advanced Parkinson's
disease: a retrospective multicenter outcome assessment in patient routine
care. J Neural Transm 2013 Nov;120(11):1553-1558.
(29) Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K,
et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N
Engl J Med 2006 Aug 31;355(9):896-908.
(30) Santos-Garcia D, Anon MJ, Fuster-Sanjurjo L, de la Fuente-Fernandez R.
Duodenal levodopa/carbidopa infusion therapy in patients with advanced
Parkinson's disease leads to improvement in caregivers' stress and burden. Eur
J Neurol 2012 Sep;19(9):1261-1265.
(31) Garcia-Gordillo M, del Pozo-Cruz B, Adsuar JC, Sanchez-Martinez FI,
Abellan-Perpinan JM. Validation and comparison of 15-D and EQ-5D-5L
instruments in a Spanish Parkinson's disease population sample. Qual Life Res
2014 May;23(4):1315-1326.
(32) Martinez-Martin P, Rodriguez-Blazquez C, Kurtis MM, Chaudhuri KR,
NMSS Validation Group. The impact of non-motor symptoms on health-related
quality of life of patients with Parkinson's disease. Mov Disord 2011 Feb
15;26(3):399-406.
(33) Martinez-Martin P, Frades Payo B. Quality of life in Parkinson's disease:
validation study of the PDQ-39 Spanish version. The Grupo Centro for Study of
Movement Disorders. J Neurol 1998 May;245 Suppl 1:S34-8.
Impacto del Estudio
Nos parece importante la realización de este estudio, porque nos va a dar la
oportunidad de llevar a cabo un seguimiento y control, más estricto en este tipo
de pacientes, estableciendo con ellos/as, una relación profesional más cercana,
que de otra manera, resulta complicado establecer en las revisiones habituales.
Además monitorizar aquellos aspectos de la vida diaria que van a ser los
responsables de su mejor o peor calidad de vida, y quizás en un futuro poder
plantearnos la posibilidad de llevar a cabo intervenciones específicas para la
mejora de los aspectos peor valorados.
En caso de que los resultados fueran discordantes con la literatura, se
podría analizar, en que varían nuestros pacientes del resto en otros estudios y
plantearnos propuestas de mejora.
ANEXO I